Bavarian Nordic Seeks EMA Approval for Mpox Vaccine Use in Children

Bavarian Nordic A/S has officially submitted clinical data to the European Medicines Agency (EMA) to expand the marketing authorization for its mpox and smallpox vaccine, MVA-BN. The application aims to include children aged 2 to 11 years, significantly broadening the vaccine's potential recipient base. This move follows positive top-line results from clinical trials, which demonstrated that the vaccine's safety profile and immune response in children are comparable to those observed in adults. Expanding the approved demographic is expected to strengthen the company’s role in global health security and increase its addressable market reach. While the news is positive for the company's growth prospects, the final impact on the stock price will depend on the EMA's ultimate regulatory decision. Investors are closely monitoring the biotech firm as it continues to address public health needs amid ongoing global health concerns.

来源:globenewswire.comguidetocanaryislands.comlifescivoice.com